Clinical trials: Acute Distress Respiratory
Acute Respiratory Distress Syndrome (ARDS), Pneumonia
Medical Device Clinical Trial Without CE Marking to Evidence Safety and Performance of the INBENTUS VERSATILE Ventilator in Patients Requiring Assisted/Controlled Mechanical Ventilation and Weaning.
Pre-market clinical trial on 81 aldults participants to evidence safety and performance of the non-CE-marked medical device INBENTUS VERSATILE ventilator.
- Conditions
- Acute Respiratory Distress Syndrome (ARDS), Pneumonia, COPD (Chronic Obstructive Pulmonary Disease), Postoperative Respiratory Distress
- Trial name
- NCT07432191
- Testing
- INBENTUS VERSATILE
- Where
- Spain
- Volunteers
- 81 people
- Sponsor
- Iconic Solutions By Murcia SL
Acute Respiratory Distress Syndrome
Noninvasive Estimation of Work of Breathing
This study will evaluate the correlation between invasively measured parameters (work of breathing/power of breathing, resistance and elastance), derived using esophageal pressure measurements, and their corresponding…
- Trial name
- NCT02867228
- Testing
- changes in ventilator settings
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Respironics, California, Inc.
ARDS, Covid19
Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS
This is a randomized, double-blinded, placebo-controlled study of AVM0703 administered as a single intravenous (IV) infusion to patients with moderate or severe immediately life-threatening Acute Respiratory Distress Syndrome…
- Conditions
- ARDS, Covid19, Influenza, Human
- Trial name
- AVM0703 (NCT04366115)
- Testing
- AVM0703
- Volunteers
- 16 people
- Sponsor
- AVM Biotechnology Inc
COVID19, ARDS
REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia
To assess the safety and efficacy of CK0802 in treatment of patients with COVID-19 induced moderate-to-severe PNA-ARDS.
- Trial name
- RESOLVE (NCT04468971)
- Testing
- CK0802
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- Cellenkos, Inc.
Respiratory Distress Syndrome
Carperitide in Acute Respiratory Distress Syndrome (ARDS)
The purpose of this study is to determine whether Carperitide is safe and effective in the management of Acute Respiratory Distress Syndrome (ARDS).
- Trial name
- NCT00030121
- Testing
- recombinant human atrial natriuretic polypeptide
- Sponsor
- Suntory Pharmaceutical
Acute Respiratory Distress Syndrome
Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19
Recent COVID 19 pandemic has overwhelmed health services all around the world, and humanity has yet to find a cure or a vaccine for the treatment of patients, mainly the severe ones, who pose a therapeutic challenge to healthcare…
- Trial name
- NCT04390152
- Testing
- Wharton's jelly derived Mesenchymal stem cells.
- Where
- 2 sites in Colombia
- Volunteers
- 6 people
- Sponsor
- BioXcellerator
Acute Respiratory Distress Syndrome, Ventilation Therapy; Complications
Phrenic Nerve Stimulation-Induced Lung ReAeration Trial
The Lungpacer PROTECT Diaphragm Pacing Therapy System (DPTS) is a temporary, percutaneously-placed, transvenous, phrenic nerve-stimulating device intended to stimulate the diaphragm to preserve and improve inspiratory muscle…
- Trial name
- PIRAT (NCT04844892)
- Testing
- Lungpacer PROTECT Diaphragm Pacing Therapy
- Where
- France
- Volunteers
- 13 people
- Sponsor
- Lungpacer Medical Inc.
Acute Respiratory Distress Syndrome
To Evaluate the Safety and Potential Therapeutic Activity of JadiCell™, an Investigational Umbilical Cord-Derived Mesenchymal Stem Cell Therapy, in Patients Diagnosed With Acute Respiratory Distress Syndrome (ARDS).
This study evaluates the safety and potential therapeutic activity of JadiCell™, an investigational umbilical cord-derived mesenchymal stem cell therapy, in patients diagnosed with Acute Respiratory Distress Syndrome (ARDS).
- Trial name
- NCT07479043
- Testing
- Subjects in the UC-MSC treatment group will receive two intravenous infusions (at day 0 and 3) of 100 million UC-MSC., Controls will receive two infusions of vehicle solution.
- Volunteers
- 128 people
- Sponsor
- Breathe Biologics, Inc.
Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome
Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients
Hospitalized patients with ARDS will be randomized to intravenous treatment with a monoclonal antibody against CD14, called IC14, or placebo. They will be followed for 28 days.
- Conditions
- Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome, Acute Lung Injury, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
- Trial name
- NCT06513949
- Testing
- Atibuclimab
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Implicit Bioscience
Covid19, ARDS
Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells for COVID-19-Induced Acute Respiratory Distress
This is a Phase 2, randomized controlled, multicenter study to assess the safety and efficacy of COVI-MSC in the setting of current standard of care (SOC) treatments for COVID-19 infection in hospitalized subjects with ARD/ARDS.
- Trial name
- NCT04728698
- Testing
- COVI-MSC
- Where
- United States
- Sponsor
- Sorrento Therapeutics, Inc.
Acute Respiratory Distress Syndrome
Mesenchymal Stem Cells for The Treatment of Acute Respiratory Distress Syndrome (ARDS)
The clinical study with UMC119-06 is designed to investigate the safety in patients with moderate acute respiratory distress syndrome ("ARDS"). This will be a dose escalation, open-label, single-center study in adult with ARDS.
- Trial name
- NCT04347967
- Testing
- UMC119-06
- Where
- Taiwan
- Volunteers
- 18 people
- Sponsor
- Meridigen Biotech Co., Ltd.
Lung Injury, Acute
SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS
This is an early phase (Phase IIa), randomized, double-blind, parallel group, multi-centre study for subjects with trauma (physical injury) who are at risk for developing Acute Lung Injury (ALI) or Acute Respiratory Distress…
- Trial name
- NCT00996840
- Testing
- SB-681323 Intravenous 3mg, SB-681323 Intravenous 7.5 mg, SB-681323 Intravenous 7.5mg
- Where
- 6 sites in United States
- Volunteers
- 77 people
- Sponsor
- GlaxoSmithKline
SARS-CoV-2, Influenza, Human
Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)
The purpose of this clinical trial is to evaluate the safety, tolerability and efficacy of two doses (dose A and dose B) of Standardized Conditioned Medium Obtained by Coculture of M2-macrophages and fat-derived Mesenchymal…
- Conditions
- SARS-CoV-2, Influenza, Human, Respiratory Syncytial Virus Infections, Respiratory Distress Syndrome
- Trial name
- NCT06684379
- Testing
- PRS CK STORM
- Where
- 3 sites in Spain
- Volunteers
- 50 people
- Sponsor
- PEACHES BIOTECH
Severe COVID-19 Disease
RAPA-501-Allo Therapy of COVID-19-ARDS
The first-in-human Phase 1 study component will evaluate two dose levels of RAPA-501-ALLO off the shelf cells in patients with COVID-19-related ARDS, with key endpoints of safety, biologic and potential disease-modifying effects.
- Trial name
- NCT04482699
- Testing
- RAPA-501-Allo off-the-shelf Therapy of COVID-19
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Rapa Therapeutics LLC
Acute Respiratory Failure, Coma
EASiVENT Study Comparing INTELLiVENT-ASV vs Non Automated Ventilation in Adult ICU Patients
The purpose of the study is to assess the safety and efficacy of INTELLiVENT-ASV (Adaptive Support Ventilation) in adult ICU patients comparing to non automated ventilation.
- Conditions
- Acute Respiratory Failure, Coma, Acute Respiratory Distress Syndrome (ARDS), Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT04400643
- Testing
- INTELLiVENT-ASV, Non-automated ventilation
- Where
- Portugal
- Volunteers
- 62 people
- Sponsor
- Hamilton Medical AG
Acute Respiratory Distress Syndrome, COVID-19
Predictors of Severe COVID-19 Outcomes
This is a longitudinal, multi-center, observational study collecting diverse biological measurements and clinical and epidemiological data for the purpose of enabling a greater understanding of the onset of severe outcomes…
- Trial name
- PRESCO (NCT04388813)
- Where
- 8 sites in United States
- Volunteers
- 494 people
- Sponsor
- Verily Life Sciences LLC
ARDS, ARDS, Human
Efficacy and Safety Evaluation of BZ371B in ARDS Patients
The purpose of this study is to evaluate safety, tolerability and efficacy of BZ371B in intubated patients with severe Acute Respiratory Distress Syndrome.
- Conditions
- ARDS, ARDS, Human, Pulmonary Disease
- Trial name
- NCT05384379
- Testing
- Inhaled BZ371B
- Where
- Brazil
- Volunteers
- 1 people
- Sponsor
- Biozeus Biopharmaceutical S.A.
COVID-19, Acute Respiratory Distress Syndrome
Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite
This multicenter, randomized, double-blind, placebo-controlled clinical trial will evaluate the efficacy and safety of intravenous Sodium Nitrite Injection for treatment of patients infected with COVID-19 who develop lung injury…
- Conditions
- COVID-19, Acute Respiratory Distress Syndrome, Acute Respiratory Failure
- Trial name
- NCT04401527
- Testing
- Sodium Nitrite, Normal Saline
- Where
- 2 sites in United States
- Sponsor
- Hope Pharmaceuticals
Acute Respiratory Distress Syndrome
A Phase 1/2 Study to Assess MultiStem® Therapy in Acute Respiratory Distress Syndrome
A study to examine the safety (and potential efficacy) of the adult stem cell investigational product, MultiStem, in adults who have Acute Respiratory Distress Syndrome (ARDS).
- Trial name
- MUST-ARDS (NCT02611609)
- Testing
- MultiStem
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 36 people
- Sponsor
- Healios K.K.
COVID, ARDS, Human
Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19)
This protocol proposes to use IC14, a recombinant chimeric monoclonal antibody (mAb) recognizing human CD14, to block CD14-mediated cellular activation in patients early in the development of ARDS.
- Conditions
- COVID, ARDS, Human, Ards, SARS-CoV2
- Trial name
- NCT04346277
- Testing
- IC14, a monoclonal antibody against CD14
- Where
- Italy
- Sponsor
- Implicit Bioscience